Skip to Main Content

  1. What are normal and stress production of endogenous corticocosteroids?

  2. What are the types of adrenal insufficiency?

  3. Which patients are at high risk of adrenal insufficiency or critical illness-related corticosteroid insufficiency and therefore may benefit from physiologic or pharmacologic steroid treatment of their illnesses?

  4. For those patients who need corticosteroid supplementation, which agents should be used, and for how long?

Adrenal insufficiency (AI) was described by Thomas Addison in 1855 as a fatal disease caused by tuberculous adrenalitis and adrenal gland failure. In 1949, the synthesis of cortisone resulted in life-saving therapy for Addison disease. However, this was shortly followed by reports of patient deaths from presumed adrenal crisis due to abrupt cortisone withdrawal in the perioperative period. These reports resulted in a new standard of administration of high doses of supplemental corticosteroids during periods of physical stress, although this practice may not be universally warranted.

Primary AI (Addison disease) refers to primary adrenal gland dysfunction. It has a prevalence of 40–110 cases per million people and an incidence of six cases per million people per year. Secondary AI denotes pituitary disease with adrenocorticotropic hormone (ACTH) hormone deficiency. The prevalence of secondary AI is approximately 150–280 per million. Hypothalamic dysfunction is responsible for tertiary AI. It usually arises after abrupt withdrawal or reduction in corticocosteroid dose, in the setting of chronic exogenous corticosteroids, and is reasonably common in the hospital setting, although the exact prevalence is unknown (Table 151-1).

Table 151-1 Primary, Secondary, and Tertiary Adrenal Insufficiency
|Download (.pdf)|Print
Practice Point
  • Common scenarios for AI in the hospital include ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.